Rodeo Therapeutics

Rodeo Therapeutics Overview

  • Founded
  • 2017
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series A1
  • Latest Deal Amount
  • $8.95M
Latest Deal Amount
  • Investors
  • 9

Rodeo Therapeutics General Information

Description

Developer of small-molecule therapies designed to promote regeneration and repair of multiple tissue types. The company's therapies increase tissue levels of prostaglandin PGE2 through inhibition of a prostaglandin-degrading enzyme (15-PGDH) and accelerate hematopoietic stem cell reconstitution following bone marrow transplant, protect against colitis and promote liver regeneration in a variety of animal models, enabling physicians to treat inflammatory bowel diseases and promote blood cell reconstitution following bone marrow transplant.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • 2815 Eastlake Avenue East
  • Suite 300
  • Seattle, WA 98102
  • United States
+1 (206) 000-0000

Rodeo Therapeutics Timeline

201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Rodeo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A1) 02-Apr-2020 $8.95M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 25-Jul-2017 00.00 00.00 000.00 Completed Generating Revenue

Rodeo Therapeutics Cap Table

To view Rodeo Therapeutics‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series AB 0,000,000 00.000000 00 00 00 00 00.00 00
Series AA 5,900,000 $0.000100 6% $1 $1 1x $0.27 34.33%
Series A 5,900,000 $0.000100 6% $1 $1 1x $1 0%

Rodeo Therapeutics Competitors (41)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Immunovative Therapies Venture Capital-Backed Jerusalem, Israel 00 000.00 000000000000 000.00
00000 000000 Venture Capital-Backed New York, NY 000.00 0000000000 0 000.00
00000 000000000000 Venture Capital-Backed South San Francisco, CA 00000 00000000000 00000
000000000 Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000000 000.00
0000000000000 0000 Formerly VC-backed Cambridge, MA 000 00000 00000000 00000

Rodeo Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Sanford Markowitz Ph.D Co-Founder & Board Member
Joseph Ready Ph.D Co-Founder
Stanton Gerson MD Co-Founder
Thong Le Chief Executive Officer, President & Board Member
David Schubert Chief Operating Officer

Rodeo Therapeutics Board Members (10)

To view Rodeo Therapeutics‘s full board member team, request access »
Name Representing Role Since
Asish Xavier Ph.D Johnson & Johnson Innovation - JJDC Board Member 000 0000
James Sullivan Ph.D Self Board Member 000 0000
Joel Marcus JD Alexandria Venture Investments Board Member 000 0000
Johnston Erwin Self Board Member 000 0000
Katie Hewitt Rodeo Therapeutics Board Member 000 0000

Rodeo Therapeutics Investors (9)

To view Rodeo Therapeutics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Accelerator Life Science Partners Venture Capital Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Eli Lilly and Company Foundation Limited Partner Minority 000 0000 000000 0

Ready to get started?

Request a free trial